Abstract：Objective To investigate the effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease. Methods A total of 100 patients with Parkinson′s disease admitted to Chenzhou NO.1 People′s Hospital, Hu′nan Province from November 2016 to October 2019 were selected and divided into the study group and the control group by random number table method, with 50 patients in each group. The control group was treated with Selegiline, and the study group was treated with Rivastigmine Hydrogen Tartrat Capsules on the basis of the control group. Both groups were treated for 8 weeks. The curative effect, the scores of WHO quality of life (WHOQOL-BREF), Parkinson′s disease rating scale (UPDRS) and autonomic nerve symptom scale (SCOPT-AUT), montreal cognitive assessment scale (MoCA), the levels of insulin-like growth factor (IGF-1), β-amyloid protein 1-42 (Aβ1-42) and dopamine transporter (DAT) activity activity in the affected side and healthy side were compared between the two groups. The adverse reactions during the treatment in both groups were recorded. Results After 8 weeks of treatment, the total clinical effective rate of the study group was higher than that of the control group, with statistically significant difference (P ＜ 0.05). After 8 weeks of treatment, WHOQOL-BREF and MOCA scores, the levels of Aβ1-42 and IGF-1 were all higher in both groups than those before treatment, and the study group was higher than the control group; UPDRS and SCOPT-AUT scores were both lower than those before treatment, and the study group was lower than the control group, with statistically significant differences (P ＜ 0.05). After 8 weeks of treatment, the DAT activity in the affected side of both groups and the healthy side of the control group decreased compared with that before treatment, and the differences were statistically significant (all P ＜ 0.05). The DAT activity in the healthy side of the study group after 8 weeks of treatment was not significantly different from that before treatment (P ＞ 0.05). After 8 weeks of treatment, the DAT activity of both the affected side and the healthy side of the study group was higher than that of the control group, with statistically significant differences (all P ＜ 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Treatment of Parkinson′s disease with Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline can rapidly improve the clinical symptoms of patients, improve serum Aβ1-42 and IGF-1 levels, delay the rate of DAT inactivation, and do not increase the incidence of adverse reactions, the effect is significant.
雷源标1 雷瑜2 欧福勇1 易继平1. 重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病的效果[J]. 中国医药导报, 2020, 17(23): 62-65,69.
LEI Yuanbiao1 LEI Yu2 OU Fuyong1 YI Jiping1. Effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease. 中国医药导报, 2020, 17(23): 62-65,69.
2020, Vol. 17 
京公网安备 11010502046598号